Gastrointestinal Stromal Tumors: all 345 studies

Page 3 of 4. Open to participants first (60), then studies with results posted, then the rest; newest registration first within each.

• MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CTCompletedNCT02931929Phase 1/2
• SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GISTSuspendedNCT02924714Not applicable
• Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTsCompletedNCT02889328Phase 2
• Feasibility and Yield of a New 20 G ProCore Needle With Coiled Sheath in the Gastrointestinal Subepithelial TumorsCompletedNCT02884154Not applicable
• Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by SurgeryCompletedNCT02880020Phase 2
• Sarcopenia in Patients With Gastrointestinal Stromal TumoursCompletedNCT02877368
• EUS-FNB vs. Single-incision Needle-knife (SINK) Biopsy for Gastrointestinal SELsStatus unknownNCT02866045Phase 3
• Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 2
• The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of RegorafenibCompletedNCT02800330Phase 4
• A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GISTStatus unknownNCT02776878Not applicable
• the Laparoscopic and Endoscopic Cooperative Surgery of Gastrointestinal Stromal TumorStatus unknownNCT02763748Not applicable
• Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal TumorWithdrawnNCT02734823
• A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTsCompletedNCT02712112Phase 2
• A Study to Evaluate the Safety of Intuvax Administered Intra-tumorally in Patients With Gastrointestinal Stromal TumorsCompletedNCT02686944Phase 1
• Laparoscopic Resection of Large Gastric Stromal TumorsCompletedNCT02662478
• Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GISTCompletedNCT02638766Phase 2
• Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and SunitinibCompletedNCT02607332Phase 2
• Regorafenib in GIST With Secondary C-KIT Exon 17 MutationCompletedNCT02606097Phase 2
• Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade IndexStatus unknownNCT02576080Phase 3
• TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid TumorsCompletedNCT02574663Phase 1
• A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced MalignanciesCompletedNCT02571036Phase 1
• Endoscopic Full Thickness Resection of Gastric Subepithelial Tumors (FROST)TerminatedNCT02488746
• Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST)Status unknownNCT02443948
• Quick Skin Sealant in Closure of Surgical Wound After Laparoscopic SurgeryStatus unknownNCT02426762Phase 2
• A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)Active, not recruitingNCT02365441Phase 2
• Prospective Cohort Study of the Clinical Applications for the Pathologic Type, Staging, and Grading of GISTStatus unknownNCT02353052
• SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)WithdrawnNCT02342600Phase 2
• A Study of Famitinib in Patients With Gastrointestinal Stromal TumorStatus unknownNCT02336724Phase 2
• GIST: Assessment of Tumor Mutations and TKI Plasma ExposureCompletedNCT02331914
• Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal TumorsWithdrawnNCT02268435Phase 1
• Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)CompletedNCT02260505Phase 3
• A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal TumorsTerminatedNCT02232620Phase 2
• Ph II CABOGIST in GISTCompletedNCT02216578Phase 2
• Influence of an Acidic Beverage on the Imatinib Exposure After Major GastrectomyTerminatedNCT02185937Phase 1
• The Oncopanel Pilot (TOP) StudyCompletedNCT02171286
• Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed ConditionsCompletedNCT02103322Phase 2/3
• Study of the Glutaminase Inhibitor CB-839 in Solid TumorsCompletedNCT02071862Phase 1
• Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of RecurrenceTerminatedNCT02009423Phase 3
• MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)Active, not recruitingNCT01991379Phase 1/2
• Regorafenib Post-marketing Surveillance in JapanCompletedNCT01933958
• Surgery for Locally Unresectable Advanced GISTs Without Metastasis After Imatinib TherapyCompletedNCT01865565
• EUS-guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle AspirationCompletedNCT01774162Not applicable
• ESTD vs. VATS for Upper Gastrointestinal Submucosal TumorsStatus unknownNCT01768104Not applicable
• A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)CompletedNCT01751919Phase 1
• Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the InvestigatorCompletedNCT01742299Phase 4
• Ipilimumab and Imatinib Mesylate in Advanced CancerCompletedNCT01738139Phase 1
• A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST PatientsCompletedNCT01735968Phase 1
• Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With ImatinibCompletedNCT01694277Phase 3
• Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)No longer availableNCT01689376
• Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard TherapyNo longer availableNCT01646593
• Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are MetastaticCompletedNCT01643278Phase 1
• Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study TerminationNo longer availableNCT01613053
• Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDIActive, not recruitingNCT01541709Phase 2
• Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and SunitinibCompletedNCT01524848Phase 2
• Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to ImatinibCompletedNCT01506336Phase 2
• Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)CompletedNCT01483014Phase 2
• A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST PatientsCompletedNCT01468688Phase 1
• Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)CompletedNCT01462994Phase 3
• The Effects of Preoperative and Postoperative Oral Nutritional Supplements in Malnourished Post-gastrectomy PatientsCompletedNCT01421680Not applicable
• Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer PatientsCompletedNCT01402089Phase 4
• A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) PatientsStatus unknownNCT01389583Phase 2
• Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine TumorsStatus unknownNCT01381822Phase 1
• Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)CompletedNCT01323400Phase 2
• A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GISTCompletedNCT01294202Phase 2
• Treatment Response Evaluation in Gastrointestinal Stromal Tumor (GIST) PatientsCompletedNCT01276483
• Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy SubjectsCompletedNCT01270984Phase 1
• Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST)WithdrawnNCT01270893Phase 2
• Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal TumorCompletedNCT01267695Phase 2
• WB-DWI for Early Prediction of Therapy Response in Patients With Advanced Metastatic GIST Treated With RegorafenibCompletedNCT01265979
• Caphosol in Oral Mucositis Due to Targeted TherapyCompletedNCT01265810Phase 3
• Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA GeneCompletedNCT01243346Phase 2
• A Retrospective Study of C-kit Mutation Status in Asian Patients With Advanced Gastro-intestinal Stromal Tumors (GIST) Treated With Imatinib.Status unknownNCT01227746
• Symptom Inventory for Gastrointestinal Stromal TumorsStatus unknownNCT01178307
• Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)CompletedNCT01172548Phase 2
• B-Receptor Signaling in CardiomyopathyCompletedNCT01135849
• Impact of the Inhibitors of Tyrosine Kinase on the Male FertilityCompletedNCT01114087Not applicable
• Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)CompletedNCT01110668Phase 2
• Sorafenib for Imatinib/Sunitinib-failed GISTCompletedNCT01091207Phase 2
• Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib MesylateCompletedNCT01046487Phase 1
• Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)CompletedNCT00998751Phase 2
• Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PKCompletedNCT00976612
• Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib MesylateTerminatedNCT00956072Phase 3
• Study of Tumor Samples in Patients Undergoing Treatment for Gastrointestinal Stromal Tumors on Clinical Trial ACOSOG-Z9001CompletedNCT00954655
• A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal TumorsCompletedNCT00940563Phase 2
• Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology SettingCompletedNCT00877045
• Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)TerminatedNCT00812240Phase 3
• Study to the Optimal Duration of Therapy With Oral Angiogenesis InhibitorsStatus unknownNCT00777504Phase 4
• Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal TumorCompletedNCT00769782Phase 2
• Permission to Collect Blood Over Time for ResearchTerminatedNCT00767234
• Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal TumorCompletedNCT00764595Phase 2
• Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and SunitinibCompletedNCT00718562Phase 2
• A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in SingaporeCompletedNCT00718211
• Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and SunitinibTerminatedNCT00688766Phase 3
• Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal TumorStatus unknownNCT00685828Phase 3
• Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal CancerCompletedNCT00654160Phase 1
• Kinase Genotyping of Gastro Intestinal Stomach Tumors (GISTs) From Patients Enrolled in Pfizer A6181112 Phase IIIb TrialWithdrawnNCT00640692
• Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) InhibitorCompletedNCT00633295Phase 2
• An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)CompletedNCT00618319Phase 2
• Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal TumorsCompletedNCT00580281Not applicable
• Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal TumorsTerminatedNCT00573404Phase 1

← Gastrointestinal Stromal Tumors overview